The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (c), Merck & Co., ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’ Substack by Magnus Ofstad. In this ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Researchers have profiled the molecular structure and features of a key part of the deadly Nipah virus. Experiments in cells ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come ...

Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy PT-101.